BTX-9341 is a Cereblon (CRBN) mediated CDK4/6 bifunctional degrader that we have developed for HR+/HER2- breast cancer. This degrader shows good exposure in brain tissues with a high …

In preclinical breast cancer models, BTX-9341 demonstrated superiority to CDK4/6 inhibitors through potent and highly selective catalytic degradation of CDK4 and CDK6, robust inhibition …

We examined retinoblastoma (RB) phosphorylation by in-cell western, E2F target gene expression by western and qPCR, cell cycle progression by flow cytometry, and cell …

2024年5月29日 · In several breast cancer xenograft models, BTX-9341 showed dose-dependent tumor growth inhibition, tumor regression at higher dose levels, and was effective with multiple …

BTX-9341是一种细胞周期蛋白依赖性激酶4（CDK4）和细胞周期蛋白依赖性激酶6（CDK6）的研究性口服和双功能降解剂，在CDK4/6抑制剂初始和耐药临床前模型中均显示出显着的抗肿瘤 …

2024年3月22日 · BTX-9341 is a Cereblon (CRBN) mediated CDK4/6 bifunctional degrader that we have developed for HR+/HER2- breast cancer. This degrader shows good exposure in …

2024年5月2日 · BTX-9341 showed potent inhibition of cell proliferation with CFA IC 50 s of < 50nM in TNBC cell lines and < 20nM in HR+ cell lines. We demonstrated that BTX-9341 was …

BTX-9341 is a potent, CRBN and proteasome dependent degrader of CDK4 and CDK6 in multiple breast cancer cell lines. CDK4/6 degradation is rapid and sustained after compound washout. …

2024年7月19日 · BTX-9341是CDK4/6的一流口服降解剂，CDK4/6是一系列癌症的重要靶标，并在HR+/HER2乳腺癌中得到临床验证。 在临床前乳腺癌模型中，BTX-9341通过对CDK4和CDK6 …

2024年7月17日 · BTX-9341 is a promising first-in-class, oral degrader of CDK4/6 that shows potential in HR+/HER2– breast cancer. Preclinically, BTX-9341 has achieved potent and …